Johnson & Johnson to expand its anti-TB programme in India

Programme aims to broaden access to treatment for multidrug-resistant strain, improve detection, build critical health systems, and raise awareness about TB at community level

Johnson & Johnson said today that it is expanding its tuberculosis (TB) programme in India ahead of the 50th Union World Conference on Lung Health in Hyderabad.

According to the company, the expanded India programme aims to broaden access to treatment for multidrug-resistant TB (MDR-TB), improve detection of undiagnosed cases, build critical health systems and raise awareness about TB at the community level. The intitiative is part of Johnson & Johnson's 10-year goal of achieving a world without TB.

"TB is a devastating disease that claims nearly half a million lives in India every year," said Sarthak Ranade, managing director, Janssen India,